Full-length CILP as a biomarker for cardiac fibrosis
AssigneeThe Regents of the University of California
InventorsReza Ardehali, Shuin Park
Life of this patent
Estimating the term…
Abstract
Methods for the detection, monitoring, and treatment of cardiac fibrosis, progression of cardiac fibrosis, or heart failure in a subject comprising: (a) contacting a sample obtained from the subject with a binding agent that binds a region of cartilage intermediate layer protein 1 (CILP) that spans the cleavage site of the CILP precursor or a nucleotide encoding same. The cardiac fibrosis may be associated with one or more of: ischemia, congenital defect, familial fibrosis, infiltrative fibrosis, idiopathic fibrosis, amyloidosis, hemosiderosis, valvular disease, and other idiopathic cardiomyopathies.
Claims8
A method for treating cardiac fibrosis, progression of cardiac fibrosis, or heart failure in a subject, the method comprising:
- (a) contacting a serum sample obtained from the subject with an antibody that binds a region of cartilage intermediate layer protein 1 (CILP) that spans the cleavage site of a CILP precursor;
- (b) measuring a decrease in the amount of CILP in the serum sample relative to a reference sample;
- and
- (c) treating the subject for cardiac fibrosis, progression of cardiac fibrosis, or heart failure when the amount of CILP in the serum sample is decreased relative to a reference sample.
Dependencies are inferred from the claim text.